Abstract:Inducing tumor-specific T cell responses and regulating suppressive tumor microenvironments have been a challenge for effective tumor therapy. CpG (ODN), the Toll-like receptor 9 agonist, has been widely used as adjuvants of cancer vaccines to induce T cell responses. We developed a novel adjuvant to improve the targeting of lymph nodes. CpG were modified with lipid and glycopolymers by the combination of photo-induced RAFT polymerization and click chemistry, and the novel adjuvant was termed as lipid-glycoadjuvant@AuNPs (LCpG). OVA protein was used as model antigen and melanoma model was established to test the immunotherapy effect of the adjuvant. In tumor model, the antitumor effect and mechanism of LCpG on the response of CTLs were examined by flow cytometry and cell cytotoxicity assay. The effects of LCpG on macrophage polarization and Tregs differentiation in tumor microenvironment were also studied by cell depletion assay and cytokine neutralization assay. We also tested the therapeutic effect of the combination of the adjuvant and anti-PD-1 treatment. LCpG could be rapidly transported to and retained longer in the lymphoid nodes than unmodified CpG. In melanoma model, LCpG controlled both primary tumor and its metastasis, and established long-term memory. In spleen and tumor draining lymphoid nodes, LCpG activated tumor-specific Tc1 responses, with increased CD8+ T-cell proliferation, antigen-specific Tc1 cytokine production and specific-tumor killing capacity. In tumor microenvironments, antigen-specific Tc1 induced by the LCpG promoted CTL infiltration, skewed tumor associated macrophages to M1 phenotype, regulated Treg and induced proinflammatory cytokines production in a CTL-derived IFN-& gamma;-dependent manner. In vivo cell depletion and adoptive transfer experiments confirmed that antitumor activity of LCpG included vaccine was mainly dependent on CTL-derived IFN-& gamma;. The anti-tumor efficacy of LCpG was dramatically enhanced when combined with anti-PD1 immunotherapy. LCpG was a promising adjuvant for vaccine formulation which could augment tumorspecific Tc1 activity, and regulate tumor microenvironments.

Delivery System of Cpg Oligodeoxynucleotides Through Eliciting an Effective T Cell Immune Response Against Melanoma in Mice

Dddt_a_325790 3953..3963

Anti-neoplasm and immuno-modification effect of novel CpG oligodeoxynucleotides in mice

Cpg Oligodeoxynucleotide Developed To Activate Primate Immune Responses Promotes Antitumoral Effects In Combination With A Neoantigen-Based Mrna Cancer Vaccine

Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.

Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice.

CpG Oligodeoxynucleotide Developed For Activating Primate Immune Responses Promotes Anti-Tumoral Effect Combine With Neo-Antigen Based mRNA Cancer Vaccine

Immunostimulatory and Anti-Neoplasm Effects of a Novel Palindrome CpG Oligodeoxynucleotide in Mice

Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma

Enhanced Immunostimulatory Activity of a Cytosine-Phosphate-Guanosine Immunomodulator by the Assembly of Polymer DNA Wires and Spheres

A Cpg Oligodeoxynucleotide Potentiates the Anti-Tumor Effect of Hsp65-Her2 Fusion Protein Against Her2 Positive B16 Melanoma in Mice

Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4+ T cells in melanomas

CpG Oligodeoxynucleotides Enhance the Efficacy of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes by Modifying the Th1 Polarization and Local Infiltration of Th17 Cells

Carbohydrate-based Adjuvants Activate Tumor-Specific Th1 and CD8+ T-cell Responses and Reduce the Immunosuppressive Activity of MDSCs

Studies on the Enhancement of DC Vaccine to Mouse Lewis Lung Cancer by CpG Oligonucleotides

Regulating tumor microenvironments by a lymph node-targeting adjuvant via tumor-specific CTL-derived IFNγ

Regulating tumor microenvironments by a lymph node-targeting adjuvant via tumor-specific CTL-derived IFN

Nanostructured SL9-CpG Lipovaccines Elicit Immune Response for the Treatment of Melanoma

Regulating the Surface Topography of CpG Nanoadjuvants Via Coordination-Driven Self-Assembly for Enhanced Tumor Immunotherapy.

Multifunctional Nanoparticles Co-Delivering Trp2 Peptide and CpG Adjuvant Induce Potent Cytotoxic T-lymphocyte Response Against Melanoma and Its Lung Metastasis

Adcances in CpG oligodeoxynucleotides in the cancer immunotherapy